

## ASAM REPRESENTATIVE



**R. Jeffrey Goldsmith, MD, DLFAPA, FASAM** joined ASAM in 1984, became ASAM certified in 1986, is an ABAM Diplomate and received his CAQ in Addiction Psychiatry in 1994. After years of involvement in ASAM committees and workgroups, Dr. Goldsmith is now the President of ASAM's Board of Directors.



**Richard G. Frank, PhD**, is the Assistant Secretary for Planning and Evaluation (ASPE), US Department of Health and Human Services. As the ASPE, Dr. Frank advises the Secretary on development of health, disability, human services, data, and science policy and provides advice and analysis on economic policy.

## ASAM CONTENT EXPERT REPRESENTATIVES



**Margaret Jarvis, MD, FASAM**, is board certified in psychiatry and addiction medicine, the Secretary of ASAM's Board of Directors, and is the Medical Director at Marworth Treatment Center in Waverly, PA. Dr. Jarvis serves as Chair of the Quality Improvement Council where she oversaw the guideline development process.



**Tom Frieden, MD, MPH**, became Director of the Centers for Disease Control and Prevention in June 2009. Dr. Frieden has worked to control health threats from infectious diseases, respond to emergencies, and battle the leading causes of suffering and death in our nation and around the world.



**Kyle Kampman, MD**, is a professor at the University of Pennsylvania and works in the Addiction Recovery Unit of the Philadelphia VA Medical Center. Dr. Kampman chaired the Guideline Committee and served as the Principal Investigator in developing ASAM's guideline.



**June S. Sivilli, MA**, serves as the Chief of the Treatment Branch in the Office of Demand Reduction, at the White House Office of National Drug Control Policy. In this role, Ms. Sivilli develops and advances the agency's demand reduction policies that integrate substance use disorder issues into mainstream health and the Affordable Care Act. (Invited to speak at the press conference).



**Nora D. Volkow, MD**, became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. NIDA supports most of the world's research on the health aspects of drug abuse and addiction.

## FEDERAL ADMINISTRATION REPRESENTATIVES



**Kana Enomoto, MA**, became the Acting Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA) in August 2015. SAMHSA is the agency within HHS that leads public health efforts to advance the behavioral health of the nation. As Acting Administrator, Ms. Enomoto oversees an agency with four centers and four offices, over 600 employees, and a budget of \$3.4 billion. Through data, policy, public education, and grants, Ms. Enomoto and the SAMHSA team advance the agency's mission to reduce the impact of substance abuse and mental illness on America's communities.

## PATIENT AND FAMILY REPRESENTATIVE



**Don Flattery, MBA**, is a member of the Virginia Task Force on Prescription Drug and Heroin Abuse, where he represents Virginia families struggling with this issue. He is assisting Fairfax County government with development of a framework for community action. He is also an impacted family member, having lost his 26-year-old son to an opioid overdose on Labor Day, 2014.

